FRANKLIN, Tenn. / Mar 03, 2025 / Business Wire / Community Health Systems, Inc. (NYSE: CYH) announced today that subsidiaries of the Company have completed the divestiture of ShorePoint Health – Port Charlotte in Port Charlotte, Florida, certain assets of ShorePoint Health – Punta Gorda, in Punta Gorda, Florida, and related businesses to subsidiaries of Adventist Health System Sunbelt Healthcare Corporation (AdventHealth) for $260 million. The entry into the definitive agreement for this transaction was announced on November 22, 2024, and the closing was effective March 1, 2025.
About Community Health Systems, Inc.
Community Health Systems, Inc. is one of the nation’s largest healthcare companies. The Company’s affiliates are leading providers of healthcare services, developing and operating healthcare delivery systems in 37 distinct markets across 15 states. The Company’s subsidiaries own or lease 73 affiliated hospitals with more than 10,000 beds and operate more than 1,000 sites of care, including physician practices, urgent care centers, freestanding emergency departments, occupational medicine clinics, imaging centers, cancer centers and ambulatory surgery centers.
The Company’s headquarters are located in Franklin, Tennessee, a suburb south of Nashville. Shares in Community Health Systems, Inc. are traded on the New York Stock Exchange under the symbol “CYH.” More information about the Company can be found on its website at www.chs.net.
Last Trade: | US$2.40 |
Daily Change: | -0.05 -2.04 |
Daily Volume: | 2,630,030 |
Market Cap: | US$333.480M |
February 18, 2025 December 11, 2024 September 16, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load